These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

459 related items for PubMed ID: 12527945

  • 1. Immunosensitization of resistant human tumor cells to cytotoxicity by tumor infiltrating lymphocytes.
    Frost P, Caliliw R, Belldegrun A, Bonavida B.
    Int J Oncol; 2003 Feb; 22(2):431-7. PubMed ID: 12527945
    [Abstract] [Full Text] [Related]

  • 2. Immunosensitization of prostate carcinoma cell lines for lymphocytes (CTL, TIL, LAK)-mediated apoptosis via the Fas-Fas-ligand pathway of cytotoxicity.
    Frost P, Ng CP, Belldegrun A, Bonavida B.
    Cell Immunol; 1997 Aug 25; 180(1):70-83. PubMed ID: 9316641
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Interleukin-2 expanded lymphocytes from lymph node and tumor biopsies of human renal cell carcinoma, breast and ovarian cancer.
    Bouet-Toussaint F, Genetel N, Rioux-Leclercq N, Bansard JY, Levêque J, Guillé F, Patard JJ, Lesimple T, Catros-Quemener V.
    Eur Cytokine Netw; 2000 Jun 25; 11(2):217-24. PubMed ID: 10903800
    [Abstract] [Full Text] [Related]

  • 5. Sensitization of human bladder cancer cells to Fas-mediated cytotoxicity by cis-diamminedichloroplatinum (II).
    Mizutani Y, Yoshida O, Bonavida B.
    J Urol; 1998 Aug 25; 160(2):561-70. PubMed ID: 9679929
    [Abstract] [Full Text] [Related]

  • 6. Sensitization of immunoresistant prostate carcinoma cell lines to Fas/Fas ligand-mediated killing by cytotoxic lymphocytes: independence of de novo protein synthesis.
    Frost PJ, Belldegrun A, Bonavida B.
    Prostate; 1999 Sep 15; 41(1):20-30. PubMed ID: 10440872
    [Abstract] [Full Text] [Related]

  • 7. Interleukin 2 expanded tumor-infiltrating lymphocytes in human renal cell cancer: isolation, characterization, and antitumor activity.
    Belldegrun A, Muul LM, Rosenberg SA.
    Cancer Res; 1988 Jan 01; 48(1):206-14. PubMed ID: 3257161
    [Abstract] [Full Text] [Related]

  • 8. Perforin-mediated lysis of tumor cells by Mycobacterium bovis Bacillus Calmette-Guérin-activated killer cells.
    Brandau S, Suttmann H, Riemensberger J, Seitzer U, Arnold J, Durek C, Jocham D, Flad HD, Böhle A.
    Clin Cancer Res; 2000 Sep 01; 6(9):3729-38. PubMed ID: 10999767
    [Abstract] [Full Text] [Related]

  • 9. Lymphocytes infiltrating human ovarian tumors: synergy between tumor necrosis factor alpha and interleukin 2 in the generation of CD8+ effectors from tumor-infiltrating lymphocytes.
    Wang YL, Si LS, Kanbour A, Herberman RB, Whiteside TL.
    Cancer Res; 1989 Nov 01; 49(21):5979-85. PubMed ID: 2507139
    [Abstract] [Full Text] [Related]

  • 10. Lymphocytes infiltrating human ovarian tumors. I. Role of Leu-19 (NKH1)-positive recombinant IL-2-activated cultures of lymphocytes infiltrating human ovarian tumors.
    Heo DS, Whiteside TL, Kanbour A, Herberman RB.
    J Immunol; 1988 Jun 01; 140(11):4042-9. PubMed ID: 3286766
    [Abstract] [Full Text] [Related]

  • 11. Interleukin-12 synergizes with interleukin-2 to generate lymphokine-activated killer activity in peripheral blood mononuclear cells cultured in ovarian cancer ascitic fluid.
    Barton DP, Blanchard DK, Duan C, Roberts WS, Cavanagh D, DeCesare S, Djeu JY.
    J Soc Gynecol Investig; 1995 Jun 01; 2(6):762-71. PubMed ID: 9420887
    [Abstract] [Full Text] [Related]

  • 12. In vitro enhanced cytotoxicity of tumor-infiltrating lymphocytes transfected with tumor necrosis factor-related apoptosis-inducing ligand and/or interleukin-2 gene in human renal cell carcinoma.
    Tian JQ, Wang ZP, Rodriguez R, Fu JS, Lu JZ, Ma BL.
    Urology; 2006 May 01; 67(5):1093-8. PubMed ID: 16635513
    [Abstract] [Full Text] [Related]

  • 13. Different expression of Fas and Fas ligand in tumor infiltrating and peripheral lymphocytes of patients with renal cell carcinomas.
    Elsässer-Beile U, Gierschner D, Welchner T, Wetterauer U.
    Anticancer Res; 2003 May 01; 23(1A):433-7. PubMed ID: 12680244
    [Abstract] [Full Text] [Related]

  • 14. Sensitization of human ovarian tumor cells by subtoxic CDDP to anti-fas antibody-mediated cytotoxicity and apoptosis.
    Uslu R, Jewett A, Bonavida B.
    Gynecol Oncol; 1996 Aug 01; 62(2):282-91. PubMed ID: 8751562
    [Abstract] [Full Text] [Related]

  • 15. The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma.
    Bennett MW, O'Connell J, O'Sullivan GC, Brady C, Roche D, Collins JK, Shanahan F.
    J Immunol; 1998 Jun 01; 160(11):5669-75. PubMed ID: 9605174
    [Abstract] [Full Text] [Related]

  • 16. Acidic pH inhibits non-MHC-restricted killer cell functions.
    Fischer B, Müller B, Fischer KG, Baur N, Kreutz W.
    Clin Immunol; 2000 Sep 01; 96(3):252-63. PubMed ID: 10964544
    [Abstract] [Full Text] [Related]

  • 17. Cytotoxic markers and frequency predict functional capacity of natural killer cells infiltrating renal cell carcinoma.
    Schleypen JS, Baur N, Kammerer R, Nelson PJ, Rohrmann K, Gröne EF, Hohenfellner M, Haferkamp A, Pohla H, Schendel DJ, Falk CS, Noessner E.
    Clin Cancer Res; 2006 Feb 01; 12(3 Pt 1):718-25. PubMed ID: 16467081
    [Abstract] [Full Text] [Related]

  • 18. Enhancement of Fas-mediated apoptosis in renal cell carcinoma cells by adriamycin.
    Wu XX, Mizutani Y, Kakehi Y, Yoshida O, Ogawa O.
    Cancer Res; 2000 Jun 01; 60(11):2912-8. PubMed ID: 10850437
    [Abstract] [Full Text] [Related]

  • 19. [Antitumor activity of human tumor infiltrating lymphocytes (TIL) and its comparison with peripheral blood lymphocytes (PBL)].
    Xu ZY.
    Zhonghua Zhong Liu Za Zhi; 1990 Sep 01; 12(5):345-7. PubMed ID: 2177396
    [Abstract] [Full Text] [Related]

  • 20. Tumor-specific lysis of human renal cell carcinomas by tumor-infiltrating lymphocytes: modulation of recognition through retroviral transduction of tumor cells with interleukin 2 complementary DNA and exogenous alpha interferon treatment.
    Schendel DJ, Gansbacher B.
    Cancer Res; 1993 Sep 01; 53(17):4020-5. PubMed ID: 8358731
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.